A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria

Niamh O'Regan1, Kristina Gegenbauer1, Jamie M O'Sullivan1

  • 1Haemostasis Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, Trinity College, Dublin, Ireland;

Blood
|October 30, 2015
PubMed

Insights

Von Willebrand factor (VWF) contributes to severe malaria. Removing VWF in mice delayed experimental cerebral malaria (ECM) progression and improved survival by reducing blood-brain barrier permeability.

Area of Science:

  • Immunology
  • Hematology
  • Pathology

Background:

  • Plasmodium falciparum malaria increases plasma von Willebrand factor (VWF) and ultra-large VWF (UL-VWF) multimers.
  • VWF's role in malaria pathogenesis is not fully understood, despite its known association with platelets.

Purpose of the Study:

  • To investigate the role of VWF in the pathogenesis of experimental cerebral malaria (ECM) using a murine model.

Main Methods:

  • Infection of wild-type (WT) and VWF knockout (VWF-/-) C57BL/6J mice with Plasmodium berghei ANKA.
  • Monitoring of clinical ECM progression, survival rates, platelet counts, blood parasitemia, and blood-brain barrier permeability.

Main Results:

  • VWF-/- mice exhibited delayed ECM progression and significantly prolonged survival compared to WT controls.
  • No significant differences in platelet counts or parasitemia were observed between VWF-/- and WT mice.
  • VWF deficiency significantly attenuated ECM-associated blood-brain barrier permeability.

Conclusions:

  • VWF plays a critical role in modulating ECM pathogenesis, independent of platelet counts or parasitemia.
  • Targeting VWF may offer a novel therapeutic strategy for reducing morbidity and mortality in cerebral malaria.